Henry Schein's Bid to Move Up the Pharma Value Chain

Henry Schein, the dental and medical supplies distributor, is known for its strong relationship with physicians' offices, where it is a major supplier of med-surge products, equipment, pharma injectables and vaccines. Now it wants to fill in gaps that pharma companies aren't paying attention to--and in the process move up the value chain. It is expanding into specialty pharmacy, and seeking to strike deals with vaccine makers. It also has set up a small business development operation to look for in-licensing opportunities.

Henry Schein Inc. , the distributor of dental and other health care products, wants to expand its presence in pharma. It's already known for a strong relationship with physicians' offices, where it is a major supplier of med-surge products, equipment and pharmaceutical injectables and vaccines. Now, it sees an opportunity to fill in gaps that pharma companies aren't paying attention to for a variety of reasons—and, in the process, move up the value chain.

Schein executives believe they can make inroads where others can't due to the company's strong, constant relationships with physicians and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.